Sutro Biopharma (STRO) Assets Average (2018 - 2025)

Sutro Biopharma has disclosed Assets Average across 8 years of filings, most recently posting $191.7 million for Q4 2025.

• Assets Average for Q4 2025 came in at $191.7 million, down 54.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $191.7 million (down 54.29% YoY), and the FY2025 annual result was $280.5 million, down 34.61% from the prior year.
• Assets Average came in at $191.7 million for Q4 2025 at Sutro Biopharma, down from $236.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $470.4 million in Q3 2024 to a low of $191.7 million in Q4 2025.
• The 5-year median for Assets Average is $379.4 million (2021), against an average of $373.1 million.
• Across the five-year window, Assets Average soared 142.6% in 2021 and plunged 54.29% in 2025, its largest moves.
• Sutro Biopharma's Assets Average stood at $356.4 million in 2021, then grew by 13.29% to $403.8 million in 2022, then advanced by 11.74% to $451.2 million in 2023, then decreased by 7.03% to $419.5 million in 2024, then slumped by 54.29% to $191.7 million in 2025.
• The last three Assets Average figures came in at $191.7 million (Q4 2025), $236.0 million (Q3 2025), and $291.9 million (Q2 2025), per Business Quant data.